Warning: Use of undefined constant auto - assumed 'auto' (this will throw an Error in a future version of PHP) in /home/biogiaco/www2/biogaiaarsredovisning.se/wp-content/themes/biogaia/functions.php on line 65
Message from the Chairman - BioGaia - Årsredovisning 2016

Message from the chairman

Successful management succession sets the stage for the future

We are summing up yet another excellent year when Axel Sjöblad and Peter Rothschild found their new roles as Managing Director and Group President. The well established business model, in combination with strong studies and products, vouches for continued success.

BioGaia has closed the books on yet another outstanding year. The company completed a smooth and successful management succession and our new Managing Director Axel Sjöblad got off to a flying start with boundless energy and a priority to quickly get ­acquainted with our key partners and provide them with effective support in their sales efforts. The transition to a role as Group President of BioGaia for our eminent founder Peter Rothschild has gone well and the company is continuing to benefit greatly from Peter’s in-depth product and research expertise in the company’s core areas.
     BioGaia has continued to drive the business model that has so successfully established the company and its excellent reputation in the financial sphere and among both medical professionals and researchers around the world.

A strong cash position

The main goals include having a close connection between sales and earnings growth, with a healthy operating margin and a generous dividend strategy for the shareholders. It is notable that the company is free from debt and has a strong cash position that not only provides scope for attractive dividends but also more than satisfies the need for investments in research and development of our current finished products as well as future potential solutions in the core area and new areas of interest.

The brand strategically important

The business model also includes a strategy to mainly use Lactobacillus reuteri in our products. Several comparative studies show that strains of Lactobacillus reuteri are superior to several other bacteria strains that are often included in the competitors’ probiotic products.
     We are continuing to develop and prioritize the BioGaia brand and this is also an important part of the strategy for future product launches.
     Finally, Biogaia’s existing products have large potential for ongoing geographical expansion and greater awareness and attention. In view of this and the exciting pipeline, I look forward to many more successful years ahead.

David Dangoor, Board Chairman, BioGaia

BioGaia year